UNASSIGNED:许多研究表明,维生素D用于治疗慢性阻塞性肺疾病(COPD)患者具有临床益处。然而,这些研究大多样本不足或结果不一致.这项荟萃分析的目的是评估维生素D治疗对COPD患者的影响。
UNASSIGNED:我们在以下电子数据库中进行了全面的检索:PubMed,Embase,科克伦图书馆,中国国家知识基础设施(CNKI),万方数据,和中国科学期刊数据库(VIP)。两名训练有素的审查人员确定了相关研究,提取的数据信息,然后通过Cochrane偏差风险评估工具评估方法的质量,独立。然后,荟萃分析由RevMan5.4进行,二元变量由风险比(RR)表示,和连续变量用平均差(MD)或标准化平均差(SMD)表示,以评估维生素D治疗COPD患者的疗效.然后,发表偏倚评估采用漏斗图分析.最后,通过GRADE系统评估证据质量.
UNASSIGNED:本研究共纳入15篇文章,涉及1598名参与者。总体结果显示,COPD患者的维生素D治疗具有统计学意义,可以显着改善1秒内的用力呼气量(FEV1),(MD:5.69,95%CI:5.01-6.38,P<0.00001,I2=51%)和FEV1/FVC(SMD:0.49,95%CI:0.39-0.60,IP<0.00001=1.05%TCI=1.84%);血清(OH急性加重次数(RR:0.40,95%CI:0.28-0.59,P<0.00001,I2=0%),和COPD评估测试(CAT)评分(MD:-3.77,95%CI:-5.86--1.68,P=0.0004,I2=79%)。
未经评估:我们的分析表明,COPD患者使用维生素D可以改善肺功能(FEV1和FEV1/FVC),血清25(OH)D,CD3+T细胞,CD4+T细胞,和T淋巴细胞CD4+/CD8+比值和减少CD8+T细胞,急性加重,CAT得分。
UNASSIGNED: Many studies have demonstrated that vitamin D has clinical benefits when used to treat patients with chronic obstructive pulmonary disease (COPD). However, most of these studies have insufficient samples or inconsistent results. The aim of this meta-analysis was to evaluate the effects of vitamin D therapy in patients with COPD.
UNASSIGNED: We performed a comprehensive retrieval in the following electronic databases: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese Scientific Journals Database (VIP). Two trained reviewers identified relevant studies, extracted data information, and then assessed the methodical quality by the Cochrane risk of bias assessment tool, independently. Then, the meta-analyses were conducted by RevMan 5.4, binary variables were represented by risks ratio (RR), and continuous variables were represented by mean difference (MD) or standardized mean difference (SMD) to assess the efficacy of vitamin D therapy in patients with COPD. Then, publication bias assessment was conducted by funnel plot analysis. Finally, the quality of evidence was assessed by the GRADE system.
UNASSIGNED: A total of 15 articles involving 1598 participants were included in this study. The overall results showed a statistical significance of vitamin D therapy in patients with COPD which can significantly improve forced expiratory volume in 1 second (FEV1) (MD: 5.69, 95% CI: 5.01-6.38,P < 0.00001,I2 = 51%) and FEV1/FVC (SMD:0.49, 95% CI: 0.39-0.60,P < 0.00001,I2 = 84%); and serum 25 (OH)D (SMD:1.21, 95% CI:1.07-1.34,P < 0.00001,I2 = 98%) also increase CD3+ Tcells (MD: 6.67, 95% CI: 5.34-8.00,P < 0.00001,I2 = 78%) and CD4+ T cells (MD: 6.00, 95% CI: 5.01-7.00,P < 0.00001,I2 = 65%); and T lymphocyte CD4+/CD8+ ratio (MD: 0.41, 95% CI: 0.20-0.61,P = 0.0001,I2 = 95%) obviously decrease CD8+ Tcells(SMD: -0.83, 95% CI: -1.05- -0.06,P < 0.00001,I2 = 82%), the times of acute exacerbation (RR: 0.40, 95% CI: 0.28-0.59,P < 0.00001,I2 = 0%), and COPD assessment test (CAT) score (MD: -3.77, 95% CI: -5.86 - -1.68,P = 0.0004,I2 = 79%).
UNASSIGNED: Our analysis indicated that vitamin D used in patients with COPD could improve the lung function (FEV1 and FEV1/FVC), the serum 25(OH)D, CD3+ T cells, CD4 + T cells, and T lymphocyte CD4+/CD8+ ratio and reduce CD8+ T cells, acute exacerbation, and CAT scores.